More about

Nonalcoholic Fatty Liver Disease

News
October 07, 2020
1 min read
Save

Testosterone in premenopausal women with NAFLD linked to higher risk for NASH, fibrosis

Young women with nonalcoholic fatty liver disease had higher testosterone levels, which led to a twofold higher risk for nonalcoholic steatohepatitis and fibrosis, according to study results.

News
October 01, 2020
3 min read
Save

Q&A: Patients with NAFLD-related cirrhosis, high BMI, psychiatric disease likely to use opioids

Q&A: Patients with NAFLD-related cirrhosis, high BMI, psychiatric disease likely to use opioids

Opioid use was more common in patients with nonalcoholic fatty liver disease with cirrhosis, higher BMI and psychiatric disease, according to a study published in Digestive Diseases.

News
September 26, 2020
3 min read
Save

Highlights from Digital ILC 2020

Healio Gastroenterology presents some of the top stories from The Digital International Liver Congress 2020.

News
September 21, 2020
1 min read
Save

Women more likely to have noncirrhotic HCC, underlying NAFLD

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology.

News
September 21, 2020
1 min read
Save

NAFLD confers twofold risk increase for incident diabetes

Patients with non-alcoholic fatty liver disease are more likely to develop diabetes, according to a meta-analysis published in Gut.

News
September 15, 2020
1 min read
Save

Asian, lean patients with NAFLD have lower prevalence of cirrhosis, CVD

Asian, lean patients with NAFLD have lower prevalence of cirrhosis, CVD

Lean Asian patients with nonalcoholic fatty liver disease had significantly lower prevalence of cirrhosis, cardiovascular disease and metabolic abnormalities than lean non-Asian patients.

News
September 03, 2020
2 min read
Save

Novel antisense drug shows promise in hypertriglyceridemia, diabetes, NAFLD

Novel antisense drug shows promise in hypertriglyceridemia, diabetes, NAFLD

Vupanorsen, an investigational antisense therapy, reduced triglyceride levels at 6 months and demonstrated benefit on additional lipid parameters compared with placebo in patients with hypertriglyceridemia, diabetes and hepatic steatosis.

News
August 29, 2020
2 min read
Save

Machine learning outperforms noninvasive tests in NAFLD

Machine learning may be a reasonable solution for screening for fatty liver in the general population in areas where more niche noninvasive tests are unavailable, according to a presenter at the Digital International Liver Congress.

News
August 29, 2020
3 min watch
Save

VIDEO: Younger people with NAFLD, COVID-19 at double risk for mortality

VIDEO: Younger people with NAFLD, COVID-19 at double risk for mortality

In this exclusive video, Thomas Berg, MD, head of the section of hepatology at The University of Leipzig, discusses data presented at The Digital International Liver Congress on the role of non-alcoholic fatty liver disease in COVID-19 mortality risk.

News
August 28, 2020
3 min read
Save

Fatty liver, cirrhosis double mortality risk in COVID-19

Through an international registry presented at the Digital International Liver Congress, experts found COVID-19 in the presence of liver disease like non-alcoholic fatty liver disease or cirrhosis conferred a greater risk for mortality and morbidity.

View more